At a glance
ClinicalIndex Comparison RecordN/ACompleted· 299 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Non Interventional Trial of Tarceva Metastatic Non Small Lung Cancer.
In Brief
An observational study evaluating Erlotinib for Non-Small Cell Lung Cancer. Completed, enrolled 299 participants across 1 site.
Detailed Summary
This is a non-interventional, open label, single arm, multicenter study to assess the safety and efficacy of erlotinib in participants with non-small cell lung cancer.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Small Cell Lung Cancer
CountriesAustria
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2008
Primary CompletionNov 2014
First PostedNov 2015
TodayJul 2026
First PostedNov 3, 2015
Enrollment StartSep 1, 2008
Primary CompletionNov 1, 2014
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 10.7 years ago
Interventions
Erlotinibdrug
Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.